Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Seminars in Musculoskeletal Radiology|January 24, 2003
Drug-induced metabolic bone disordersJack LawsonVeterinary Record Open|August 3, 2023
Analysis of lower urinary tract signs and bacteriuria in cats with subcutaneous ureteral bypass systemsLuba Djoneva, Jack Lawson, Lynda Rutherford, et al.Journal of Veterinary Internal Medicine|February 26, 2026
Chronic inflammatory enteropathy without moderate to severe hypoalbuminemia: long-term outcome in 60 dogsSarah Caulfield, Simon L Priestnall, Jack Lawson, et al.Journal of the American Veterinary Medical Association|December 24, 2025
Association of preoperative anemia on perioperative complications and short-term outcomes in cats undergoing subcutaneous ureteral bypassJoe Simon, Thomas Livingstone, Jack Lawson, et al.The Journal of Clinical Endocrinology and Metabolism|December 18, 2021
An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regressionIldiko Lingvay, Robert Bauer, James Baker-Knight, et al.Veterinary Journal (London, England : 1997)|December 6, 2014
Renal fibrosis in feline chronic kidney disease: known mediators and mechanisms of injuryJack Lawson, Jonathan Elliott, Caroline Wheeler-Jones, et al.Ecology and Evolution|February 22, 2024
Acoustic features as a tool to visualize and explore marine soundscapes: Applications illustrated using marine mammal passive acoustic monitoring datasetsSimone Cominelli, Nicolo' Bellin, Carissa D Brown, et al.Endocrinology, Diabetes & Metabolism|July 19, 2021
A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular diseaseLyndon Marc Evans, Linda Mellbin, Pierre Johansen, et al.Diabetes, Obesity & Metabolism|October 17, 2022
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11Marc Evans, Barrie Chubb, Samuel J P Malkin, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 26, 2022
An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal-Bolus Insulin in Type 2 DiabetesIldiko Lingvay, Andrei-Mircea Catarig, Jack Lawson, et al.Pageof 3